Monte Rosa Therapeutics ($GLUE) Insider Trading & Smart Money Activity
Monte Rosa Therapeutics, Inc. ($GLUE) has 30 insider trades, 1 13F position change and 1 analyst rating on file. In the last 12 months on the open market, no insider bought and 5 insiders sold ($1.11M), net -$1.11M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 5
- Net insider $ (12 mo)
- -$1.11M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 1
- Analyst ratings on file
- 1
GLUE insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 5 · $1.11M | 0 / 0 | 0 / 0 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 1 · $137.28 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All GLUE insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Bowen MatthewPrincipal Accounting Officer | Sell (Open-market sale) | 13 sh | $137.28 | +2.4% | — | |||||
| Analyst | Guggenheim | Reiterates to buy | PT $35 | +0.8% | -6.3% | Read | |||||
| Insider | Anthony Manning | Sell (Open-market sale) | 10K sh | $231.10K | -2.7% | -9.8% | Read | ||||
| Insider | Anthony Manning | Buy (Option exercise) | 10K sh | $41.60K | -2.7% | -9.8% | Read | ||||
| Insider | Filip JankuChief Medical Officer | Sell (Open-market sale) 10b5-1 | 6K sh | $137.70K | -2.7% | -9.8% | Read | ||||
| Insider | Filip JankuChief Medical Officer | Buy (Option exercise) | 6K sh | $45.36K | -2.7% | -9.8% | Read | ||||
| Insider | Filip JankuChief Medical Officer | Sell (Open-market sale) 10b5-1 | 30K sh | $642.60K | +15.2% | +9.3% | — | ||||
| Insider | Filip JankuChief Medical Officer | Buy (Option exercise) | 30K sh | $226.80K | +15.2% | +9.3% | — | ||||
| Insider | Sharon TownsonChief Scientific Officer | Sell (Option exercise) | 3K sh | +16.9% | +11.2% | — | |||||
| Insider | Sharon TownsonChief Scientific Officer | Buy (Option exercise) | 3K sh | $18.42K | +16.9% | +11.2% | — | ||||
| Insider | Filip JankuChief Medical Officer | Sell (Option exercise) | 6K sh | +16.9% | +11.2% | — | |||||
| Insider | Filip JankuChief Medical Officer | Buy (Option exercise) | 6K sh | $45.36K | +16.9% | +11.2% | Read | ||||
| Insider | Jennifer ChampouxChief Operating Officer | Sell (Option exercise) | 2.17K sh | +16.9% | +11.2% | — | |||||
| Insider | Jennifer ChampouxChief Operating Officer | Buy (Option exercise) | 2.17K sh | $8.66K | +16.9% | +11.2% | — | ||||
| Insider | Sharon TownsonChief Scientific Officer | Sell (Open-market sale) 10b5-1 | 3K sh | $57K | +13.3% | +33.4% | — | ||||
| Insider | Sharon TownsonChief Scientific Officer | Buy (Option exercise) | 3K sh | $18.42K | +13.3% | +33.4% | — | ||||
| Insider | Jennifer ChampouxChief Operating Officer | Sell (Open-market sale) 10b5-1 | 2.18K sh | $41.34K | +13.3% | +33.4% | — | ||||
| Insider | Jennifer ChampouxChief Operating Officer | Buy (Option exercise) | 2.18K sh | $8.66K | +13.3% | +33.4% | — | ||||
| Insider | Jan Skvarka | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Christine Siu | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Christine Siu | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Andrew Schiff | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Andrew Schiff | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Anthony Manning | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Anthony Manning | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Eric Hughes | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Eric Hughes | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Kimberly Blackwell | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Kimberly Blackwell | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Ali Behbahani | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| Insider | Ali Behbahani | Buy (Grant or award) | 25.80K sh | +7.1% | +28.5% | — | |||||
| 13F | Avoro Capital Advisors | Sold out | -3.73M sh | Read |
1W / 1M / 6M = how GLUE moved from the trade or filing date.
Insider trading in GLUE: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Bowen Matthew | Principal Accounting Officer | 1 | -$137.28 | Oct 5, 2026 | |
| Filip Janku | Chief Medical Officer | 6 | -$780.30K | Jun 29, 2026 | |
| Anthony Manning | 4 | -$231.10K | Jun 29, 2026 | ||
| Sharon Townson | Chief Scientific Officer | 4 | -$57K | Jun 23, 2026 | |
| Jennifer Champoux | Chief Operating Officer | 4 | -$41.34K | Jun 23, 2026 | |
| Christine Siu | 2 | — | Jun 11, 2026 | ||
| Andrew Schiff | 2 | — | Jun 11, 2026 | ||
| Eric Hughes | 2 | — | Jun 11, 2026 | ||
| Kimberly Blackwell | 2 | — | Jun 11, 2026 | ||
| Ali Behbahani | 2 | — | Jun 11, 2026 | ||
| Jan Skvarka | 1 | — | Jun 11, 2026 |
Institutions moving GLUE (13F)
Analyst ratings on GLUE
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Guggenheim | Reiterates | buy | $35 | +0.8% | -6.3% | Read |
Frequently asked questions
Are GLUE insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 5 insiders made 6 open-market sales worth $1.11M, a net -$1.11M.
What is the latest insider trade in GLUE?
Bowen Matthew, Principal Accounting Officer filed a sell (open-market sale) of 13 sh worth $137.28 on Oct 5, 2026.
Which institutions changed their GLUE positions?
Recent 13F filers moving the stock include Avoro Capital Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.